那天凌晨將近兩點,34歲的M先生被警察送進了我們的急診室。鄰居聽到他在走廊大聲吼叫,於是報了警。他已經四天沒有睡覺,堅信自己公寓的電線被人換過,為的是要錄下他的一舉一動。他的指尖上留著割傷,是他一個個翻找插座時弄傷的。

他不是第一次來了。之前已經住院三次,每一次出院,手上都多了一袋藥和一張回診單。我輕聲問他,有沒有按時吃奧氮平,他看起來幾乎有些被冒犯。「我覺得自己好好的,」他說,「吃了藥腦袋昏昏沉沉的,夏天我就停了。」接著,他說出了一句我聽過數百位病人用不同方式說過的話:「我沒有病,我只是受夠了別人一直告訴我該吃什麼。」

我給了他一條毯子、一個三明治和一間安靜的房間,然後坐下來聽他說。接下來的幾週,等他穩定下來,我們談到了另一種方式。不是換診斷,也不是換藥,而是換一種把同樣的藥送進身體的方法。一種不必每天都要記得,也不必每天都被提醒「我生病了」的方法。

簡單說,這場談話,正是本月稍早一則法規新聞比聽起來更重要的原因。

用一針,取代每晚的提醒

2026年10月9日,美國食品藥物管理局(FDA)核准了Weltruza,這是專為成人思覺失調症患者設計的一種新型奧氮平。它由梯瓦製藥(Teva Pharmaceuticals)推出,屬於長效針劑(long-acting injectable,簡稱LAI),每個月於皮下注射一次。藥廠表示,幾週內就會在美國上市。

奧氮平本身並不新。數十年來,它一直是精神科的主力藥物,在新一代抗精神病藥物中,它的口服藥丸仍是處方最廣的一種。真正新的是它的遞送方式。法國公司Medincell研發了一種特殊的緩釋聚合物,把藥物包覆其中,讓藥物在大約一個月的時間裡穩定地慢慢釋出,血中濃度因此相當平穩,不像每天吃藥丸那樣忽高忽低。

Weltruza有三種劑量,分別是318、425和531毫克,對應多年來醫師開立的每日10、15和20毫克藥丸。簡單說,一針就能取代大約三十天的藥丸。

到底什麼是長效針劑?

如果「長效針劑」這四個字讓你想到的是令人害怕的畫面,請讓我把它說得柔和一些。長效針劑其實只是把藥物做成緩慢釋放的劑型。病人不必每天吞一顆藥,而是每隔幾週或幾個月,到診所或醫院打一針。藥物屬於同一類,只是給藥的節奏完全不同。

這個點子其實很老了。第一批注射型抗精神病藥物在1960年代就出現了,而且長久以來背負著一個不公平的名聲,彷彿是一種強硬的手段,是「對病人做」的事,而不是「與病人一起」做的事。這種印象消退得很慢,儘管新一代的針劑更溫和、種類更多,也常常是病人自己選擇的。

它們為什麼會存在?因為治療思覺失調症的核心有一個頑固的難題:要連續好幾年每天按時吃藥,本來就很不容易,更何況病症的一部分,有時正是意識不到自己生病了。研究估計,多達一半的思覺失調症患者難以按醫囑服藥,而停藥後復發的風險,是持續服藥者的二到六倍。每一次復發,都可能讓人丟掉工作、失去感情、失去住處,有時還會損失一點腦部功能。

為什麼有人選擇打針

我想在這裡小心地說明一件事,因為常見的說法是,針劑是給那些「不能信任他們會吃藥」的人用的。這不是我在診間聽到的。以下是病人實際告訴我他們喜歡的地方:

• **不必每天被提醒。**流理台上的藥瓶,有時像是貼在額頭上的標籤。每個月打一針,代表疾病在其餘二十九天裡佔的位置小了許多。
• **不會不小心漏藥。**生活本來就忙亂。人會忘記、會出遠門、會藥吃完了、會弄丟錢包、會換藥局。
• **家人比較安心。**父母和伴侶常常不情願地變成「吃藥糾察隊」。把這份工作從他們肩上卸下,可以修補那個藥瓶悄悄傷害過的關係。
• **藥物濃度更穩定。**血中濃度平穩,可能代表情緒與症狀的起伏比較少。

臨床醫師也喜歡,原因很簡單:打針的話,我們馬上就知道哪一次沒來。錯過一次回診是一個訊號,而不是三個月後,在凌晨兩點的急診室裡才發現的謎團。

而研究結果令人鼓舞,只是比宣傳文宣複雜一些。追蹤同一批病人,比較他們從藥丸改為針劑前後的研究發現,住院的次數大幅下降,其中一篇重要的回顧指出,使用針劑時住院的風險,不到使用藥丸時的一半。大型隨機對照試驗的結果則比較分歧,部分原因是願意參加研究的人,通常比一般病人更擅長按時吃藥。一項2024年針對疾病早期患者的分析發現,針劑與藥丸整體上沒有顯著差異,但在設計較嚴謹、較貼近真實臨床的研究中,針劑領先,而且從未見到藥丸勝出。誠實的結論是:針劑不是魔法,但對許多人來說,它讓天平更傾向於維持健康。

S太太與她「忘了」的那一針

S太太今年58歲,是一位鋼琴老師,二十多歲起就與思覺失調症共處。多年來,她反覆住院,通常是因為覺得好多了,就悄悄停了藥。八年前,她開始每月注射另一種抗精神病藥物的長效針劑,她的生活也因此改變了,只是改變得不夠戲劇化,上不了新聞頭條。她帶同一批學生已經七年,她主辦過感恩節晚餐。她曾對我說:「這是我唯一不必去想的藥。」

更早以前,她吃奧氮平藥丸的效果很好,在她看來,比其他任何藥都好。但她胖了四十多磅,血糖也慢慢爬高,於是自己停了藥。當我告訴她有新的奧氮平針劑時,她的眼睛先是一亮,隨即又黯淡下來,幾乎在同一口氣之間。「它會讓我的體重變成那樣嗎?」她問。

這是個很好的問題,誠實的答案是:有可能。我們稍後再回頭談這件事。

舊版奧氮平針劑的難題

故事有趣的地方來了。其實奧氮平早已有長效針劑,已經上市多年,是肌肉注射的劑型,商品名是Zyprexa Relprevv。它有效,但有一個附帶條件,讓大多數病人都用不上。

少數病人,雖然罕見,但很可怕,會在注射後出現一種叫做「注射後譫妄/鎮靜症候群」(PDSS)的反應。他們可能變得極度嗜睡、意識混亂、站立不穩,甚至短暫沒有反應。這似乎是因為藥物太快大量進入血液所造成。也因此,FDA對這款舊針劑要求了一套安全計畫:必須在經過認證的醫療機構注射,而且每一次注射後,病人都必須留下觀察三個小時。

想一想這在現實生活中意味著什麼。想像你住在離最近的認證診所九十分鐘車程的地方,工作沒有帶薪假,要靠公車或姊姊載你。三小時的觀察,再加上來回的路程,可能吃掉整整一天。對許多人來說,那不是一道門檻,而是一堵牆。

T先生與那三個小時的牆

T先生29歲,在倉庫工作。他試過的所有藥物中,奧氮平是唯一一種讓幻聽安靜下來、讓他能清楚思考的藥。問題是,他是那種會忘記吃藥的人。每一次中斷,幻聽就會在幾週內回來。

我們討論了舊的奧氮平針劑,他安靜了一會兒,然後說:「我沒辦法每個月請半天假,我會被開除的。」他說得沒錯。如今他打的是另一種針劑,效果還算不錯,但他形容它是「還可以,不算很好」。這正是我們在門診天天面對的取捨:對病人最好的藥,不一定是病人在現實中真正拿得到的那一種。

當我告訴他新藥獲准的消息時,他問了我聽過的病人所問過最實際的問題:「所以我就是進去、打針、然後離開?」

如果這些數據在日常臨床中站得住腳,那麼答案是:對。這或許正是這款新核准的奧氮平針劑最值得一提的好處之一。

證據怎麼說

這次核准主要依據一項名為SOLARIS的試驗,共納入675位正處於症狀惡化期的成年思覺失調症患者。在最初八週,受試者接受三種劑量之一的針劑,或接受安慰劑。與安慰劑相比,三種劑量都在標準量表上改善了症狀,幅度大約是十分,藥廠也報告,整體疾病嚴重度以及個人與社會功能同樣有明顯進步。長達56週的追蹤顯示,療效似乎能持續。

在藥廠後來發表的一項分析中,56%的病人達到研究者所稱的「穩定」,而在治療滿六個月以上的183人中,約21%達到緩解。這些數字令人鼓舞,但它們來自藥廠,仍有待獨立研究者與真實世界的經驗來驗證。

平靜的代價:體重、血糖與嗜睡

現在回到S太太的問題。我若不明白地說,就是對讀者失職:這款新針劑並沒有改變奧氮平最令人困擾的副作用。

奧氮平以造成體重增加,以及血糖與膽固醇改變而聞名。在SOLARIS試驗中,持續注射48週以上的人,平均增加約5.6公斤,大約12磅。在較短的急性期,治療組平均增加近7公斤,安慰劑組則約2.3公斤。研究者表示,這樣的模式與口服藥丸相似,而且幾個月後似乎會趨於平緩,但就個人而言,實際增加的數字可能高出許多,也可能低得多。

其他常見的副作用有嗜睡、頭痛、便秘,以及注射部位的反應,例如痠痛、硬塊、發紅和發癢。注射部位的疼痛與硬塊,各有大約八分之一的人出現。這些大多為輕度到中度,因副作用而退出試驗的比率很低,而且與安慰劑相近。每月一針的藥,如果你覺得很不舒服,也比較難很快停下來。藥丸明天就可以不吃,針劑的藥效卻會持續好幾週。這就是為什麼許多臨床醫師通常會希望,先確定病人能耐受口服劑型,再開始長效針劑,也是為什麼從第一個月起,仔細監測體重、血糖和膽固醇就非常重要。此外,也有一些方法可以幫助減緩體重增加,從營養與運動的協助,到其他藥物,都值得與你的照護團隊一起討論,而不是獨自面對。

長效針劑的選擇一覽

Weltruza加入了一個日漸壯大的家族。以下是一趟簡短的巡禮,給好奇的讀者:

• **氟哌啶醇與氟非那嗪的癸酸酯針劑。**老前輩,出現於1960與1970年代。它們價格低廉、仍然有效,但比較容易引起僵硬、顫抖和坐立不安。
• **利培酮針劑(Risperdal Consta、Perseris、Uzedy)。**Consta是每兩週肌肉注射一次。Perseris與Uzedy比較新,是皮下注射,在形式上與Weltruza最為接近。
• **帕利哌酮針劑(Invega Sustenna、Trinza、Hafyera)。**注射間隔從每月一次,延長到每三個月,甚至每六個月一次,對不喜歡常跑醫院的人來說,方便得驚人。
• **阿立哌唑針劑(Abilify Maintena、Abilify Asimtufii、Aristada)。**間隔從每月一次到每兩個月一次,當體重增加是主要顧慮時,常被選用,因為阿立哌唑對體重與代謝的影響,通常比奧氮平溫和。
• **奧氮平帕莫酸鹽(Zyprexa Relprevv)。**先前唯一的奧氮平選項,有效,但需要三小時的觀察。

那麼,Weltruza與它們相比如何?它的突出之處,在於把奧氮平這個藥效強大、廣受信賴的藥物,以皮下注射的方式提供,而且不必待在候診室裡。它可能落後的地方,一是頻率(每月一次,而部分帕利哌酮產品可以延長到三個月或六個月),二是代謝方面的副作用(阿立哌唑和其他一些藥物通常比較溫和)。更重要的是,這次核准依據的是一項安慰劑對照試驗,而不是與其他針劑的直接比較,因此我們還不知道它在正面對決中表現如何。最好的針劑,是某位病人真正能夠拿到、也能夠耐受的那一種。

針頭之外:還有什麼正在到來

長效奧氮平,是用更好的方式遞送一個老點子。但這個領域,終於也看到了一些真正全新的想法。

在過去大約七十年裡,幾乎每一種抗精神病藥物,都是以某種方式,透過調節大腦的多巴胺訊號來發揮作用。2024年9月,FDA核准了Cobenfy,這是一種作用在完全不同系統上的藥丸,即大腦的蕈毒鹼受體。它是數十年來第一種新類型的思覺失調症藥物。早期試驗顯示,它能有意義地緩解症狀,而且沒有常見的體重增加或僵硬問題,不過噁心、便秘和口乾很常見。它並不是完美的答案:一項測試它作為附加治療,用於目前抗精神病藥物效果不足者的試驗,沒有顯示出統計上顯著的益處,而且它仍然必須每天服用兩次,這又把長效針劑想要解決的服藥順從性問題帶了回來。研究者也在研究它是否能用於阿茲海默症伴隨的幻覺與躁動。

其他被寄予厚望的藥物則跌了跤。一種備受關注的藥物emraclidine,在兩項中期試驗中未能勝過安慰劑,這提醒了我們,開發精神科藥物有多麼困難。其他藥物,包括針對蕈毒鹼系統的新藥,以及像brilaroxazine這樣的藥物,仍在試驗的路上前進。

而對於約三分之一對標準抗精神病藥物沒有反應的人,氯氮平仍然是我們手上最有效的選擇。它之所以未被充分使用,部分是因為需要抽血監測,而且目前沒有長效劑型。

未來很可能像一份菜單,而不是單一贏家:為對舊藥沒有反應的人,提供新的作用機制;為對藥物有反應、卻難以每天服藥的人,提供更好的遞送系統,像Weltruza這樣的產品。

藥物無法獨自完成的事

我想用一句我希望更多新聞標題會說的話來作結。一針,並不能治療思覺失調症。它治療的,是思覺失調症中藥物所能觸及的那一部分。

急診室裡的那位M先生,後來終於同意接受每月一針。這不是奇蹟。他偶爾還是會聽到有人低聲喚他的名字,睡眠仍然是個難題。但他從此沒有再住院,上個月他告訴我,他開始到社區菜園當志工。把小鏟子放進他手裡的,不是那一針。是住宿協調員、同儕支持團體、幫他理解自己經驗的心理師、每個週日都會打電話來的哥哥,以及一長串微小而充滿人味的事物。那一針所做的,只是讓腳下的地板不至於塌陷,好讓這一切有地方可以站立。

我想,這才是長效藥物真正的承諾:不是治癒,而是守護那些平凡安靜的日子,因為一個人的生活,正是在這樣的日子裡,一點一點重新蓋起來的。

作者：Dr. Bob Lee, DO, MS, MBA
Chief Resident Physician, Department of Psychiatry & Behavioral Sciences
Child and Adolescent Psychiatry Fellow
Nassau University Medical Center

————————————————————————————————————————————————————————————————————————————–

A Slow-Release Kind of Hope

Long-acting injectables, and why a new monthly olanzapine shot matters

It was nearly two in the morning when Mr. M, a 34-year-old man, was brought into our emergency room by police. A neighbor had called after hearing him shouting in the hallway. He had not slept in four days. He was certain that the wiring in his apartment had been replaced to record him, and he had the cut fingertips to show for his search through the outlets.

He had been here before. Three earlier hospital stays, each ending with a bag of pills and a follow-up appointment. When I asked, gently, whether he was taking his olanzapine, he looked almost offended. “I felt fine,” he said. “The pills made me foggy. I stopped in the summer.” Then he added the sentence I have heard, in different words, from hundreds of patients: “I’m not sick. I’m just tired of being told what to take.”

I gave him a blanket, a sandwich, and a quiet room, and I sat down and listened. In the weeks that followed, once he was stable, we talked about another way. Not a different diagnosis or a different drug, but a different way of getting the same medicine into his body. Ones that did not depend on remembering, every single day, something that reminded him of being ill.

That conversation is, in a nutshell, why a piece of regulatory news from earlier this month matters more than it may sound.

A Needle Instead of a Nightly Reminder

On October 9, 2026, the U.S. Food and Drug Administration approved Weltruza, a new form of olanzapine for adults with schizophrenia. Made by Teva Pharmaceuticals, it is a long-acting injectable, or “LAI,” given just under the skin once a month. The company says it will reach U.S. pharmacies in the coming weeks.

Olanzapine itself is not new. It has been a workhorse of psychiatry for decades, and it remains the most widely prescribed of the newer-generation antipsychotics in its daily pill form. What is new is the delivery system. A special slow-release polymer, developed by a French company called Medincell, holds the medication and lets it seep out steadily over about a month, so the level in the blood stays fairly even instead of spiking and dipping the way it does with a daily tablet.

Weltruza comes in three doses, 318, 425 and 531 milligrams, which correspond to the 10, 15 and 20 milligram daily pills that doctors have prescribed for years. To put it simply, one injection replaces about thirty days of pills.

What Is a Long-Acting Injectable, Anyway?

If the phrase “long-acting injectable” conjures a frightening image, let me soften it. An LAI is simply a medication packaged so that it releases slowly. Instead of swallowing a tablet every day, a person receives a shot every few weeks or months, in a doctor’s office or clinic. The medicine is the same family of medicine, but the schedule is completely different.

The idea is old. The first injectable antipsychotics appeared in the 1960s, and for decades they carried an unfair reputation as a heavy-handed tool, something done to patients rather than with them. That reputation has been slow to fade, even though the newer injectables are gentler, more varied, and often chosen by patients themselves.

Why do they exist at all? Because of a stubborn problem at the heart of treating schizophrenia: it is very hard to take a pill every day for years, especially when part of the illness can be not realizing you are ill. Researchers have estimated that up to half of people with schizophrenia struggle with taking their medication as prescribed, and the risk of relapse is two to six times higher without it. Every relapse can cost a person a job, a relationship, an apartment, and sometimes a little more brain function than they had before.

Why People Choose the Shot

I want to be careful here, because the usual story told by doctors is that injectables are for people who “can’t be trusted” to take pills. That is not what I hear in my office. Here is what patients actually tell me they like:

• Freedom from the daily reminder. A pill bottle on the counter can feel like a sign on the forehead. One shot a month means the illness takes up less room in the other twenty-nine days.
• Fewer missed doses by accident. Life is chaotic. People forget, travel, run out, lose their wallet, change pharmacies.
• Peace of mind for families. Parents and partners often become unwilling pill police. Lifting that job from them can repair relationships that the pill bottle quietly damaged.
• A steadier level of medicine. Smooth blood levels can mean fewer ups and downs.

Clinicians like them too, for a very simple reason: with an injection, we know right away when a dose has been missed. A missed appointment is a signal, not a mystery discovered three months later in an emergency room at 2 a.m.

And the research is encouraging, if more complicated than the marketing. Studies that follow the same patients before and after switching from pills to injections have found large drops in hospital stays, with one major review reporting that the risk of hospitalization on an injectable was less than half what it was on pills. Large randomized trials have been more mixed, partly because people who agree to join a research study tend to be better at taking pills than the average patient. A 2024 analysis focused on people early in their illness found no overall difference between injections and pills, but it did find that injectables came out ahead in the better-designed and more real-world studies, and it never found pills winning. The honest summary is this: injectables are not magic, but for many people they tilt the odds toward staying well.

Mrs. S and the Shot She Forgets About

Mrs. S is a 58-year-old piano teacher who has lived with schizophrenia since her twenties. For years she cycled through hospital stays, usually after she felt better and quietly stopped her medication. Eight years ago she began a monthly injectable of a different antipsychotic, and her life changed in ways that are not dramatic enough for a headline. She has kept the same students for seven years. She hosted Thanksgiving. She told me once, “It’s the one medicine I never have to think about.”

Years before, she had done well on olanzapine pills, better, in her view, than on anything else. But she had gained more than forty pounds, her blood sugar had crept up, and she stopped it herself. When I told her about the new olanzapine shot, her eyes lit up and then dimmed in the same breath. “Does it do the same thing to my weight?” she asked.

It was the right question, and the honest answer is yes, it can. We will come back to that.

The Problem with the Old Olanzapine Shot

Here is where the story gets interesting. Olanzapine has actually been available as a long-acting injection for years, in an intramuscular form that goes by the name Zyprexa Relprevv. It works, but it comes with a catch that has kept it out of reach for most patients.

A small number of patients, a rare but frightening few, experience a reaction after the injection called post-injection delirium/sedation syndrome, or PDSS. People can become extremely drowsy, confused, unsteady, or even briefly unresponsive. It seems to happen when too much medicine enters the bloodstream too quickly. Because of this, the FDA requires a safety program for the old injection: it must be given in a certified health facility, and the patient must stay for three hours of observation afterward, every single time.

Think about what that means in real life. Imagine living ninety minutes from the nearest certified clinic, holding a job without paid time off, relying on a bus or a ride from your sister. Three hours of observation, plus travel, can swallow an entire day. For many people, that is not a hurdle. It is a wall.

Mr. T and the Three-Hour Wall

Mr. T is a 29-year-old man who works in a warehouse. Of all the medicines he has tried, olanzapine is the one that quieted the voices and let him think clearly. The trouble is that he is a person who forgets pills. After each lapse, the voices came back within weeks.

We discussed the old olanzapine injection, and he sat quietly for a moment and said, “I can’t take a half day off every month. I’ll get fired.” And he was right. He is still on a different injectable today, one that works reasonably well but that he describes as “fine, not great.” It is the trade-off many of us make in the clinic every day: the best drug for the person is not always the one the person can realistically receive.

When I told him about the new approval, he asked the most practical question I have ever heard from a patient: “So I just go in, get the shot, and leave?”

If the data hold up in everyday practice, then yes. That is, perhaps, one of the most noteworthy benefits of this newly-approved injectable olanzapine.

What the Evidence Shows

The approval rests mainly on a trial called SOLARIS, which enrolled 675 adults with schizophrenia who were experiencing a flare of symptoms. For the first eight weeks, participants received one of three doses of the injection or a placebo. All three doses improved symptoms on a standard rating scale compared with placebo, by roughly ten points, and the company reports meaningful improvements in overall illness severity and in personal and social functioning as well. Longer follow-up, up to 56 weeks, suggested the benefits lasted.

In a later analysis presented by the company, 56% of patients reached what the researchers call stability, and among 183 people treated for six months or more, about 21% reached remission. Those are encouraging numbers, though they come from the manufacturer and deserve to be confirmed by independent researchers and real-world experience.

The Cost of Calm: Weight, Sugar, and Sleepiness

Now to Mrs. S’s question. I would be doing readers a disservice if I did not say clearly: this new injection does not change olanzapine’s most troublesome side effect.

Olanzapine is well known for causing weight gain and shifts in blood sugar and cholesterol. In SOLARIS, people who stayed on the injection for 48 weeks or more gained an average of about 5.6 kilograms, or roughly 12 pounds. During the shorter acute phase, the average gain was nearly 7 kilograms in the treated group compared with about 2.3 in the placebo group. The researchers say the pattern matches what is seen with the pills, and it does appear to level off after several months, but for any individual, the number can be much higher or lower.

Other common side effects were sleepiness, headache, constipation, and reactions at the injection site, such as soreness, hardness, redness, and itching. Injection-site pain and firmness each occurred in about one in eight people. Most of these were mild to moderate, and the rate of people quitting the study because of side effects was low and similar to placebo. A monthly injection is harder to stop quickly if you feel awful on it. A pill can be dropped tomorrow. A shot lingers for weeks. That is why many clinicians, in general, like to be sure a person tolerates the oral version before starting a long-acting one, and why careful monitoring of weight, blood sugar, and cholesterol matters from the first month. There are also steps that can help blunt weight gain, from nutrition and exercise support to other medicines, which are worth discussing with your care team rather than facing alone.

A Gallery of Long-Acting Options

Weltruza joins a growing family. A very brief tour for the curious:

• Haloperidol and fluphenazine decanoate. The old guard, from the 1960s and 1970s. They remain inexpensive and effective, but they are more likely to cause stiffness, tremor, and restlessness.
• Risperidone injections (Risperdal Consta, Perseris, Uzedy). Consta is given into a muscle every two weeks. Perseris and Uzedy are newer and go under the skin, which brings them closest in style to Weltruza.
• Paliperidone injections (Invega Sustenna, Trinza, Hafyera). These stretch out from monthly to every three months and even every six months, a remarkable convenience for people who dislike frequent visits.
• Aripiprazole injections (Abilify Maintena, Abilify Asimtufii, Aristada). These range from monthly to every two months and are often chosen when weight gain is a major concern, since aripiprazole tends to be gentler on weight and metabolism than olanzapine.
• Olanzapine pamoate (Zyprexa Relprevv). The previous olanzapine option, effective but requiring the three-hour monitoring.

How does Weltruza compare? Where it stands out is in offering olanzapine, a potent and well-loved drug, under the skin with no waiting room required. Where it may lose ground is on frequency (monthly, while some paliperidone products stretch to three or six months) and on metabolic side effects (where aripiprazole and some others tend to be kinder). Importantly, the approval rests on a placebo-controlled trial, not on a head-to-head comparison with other injectables, so we do not yet know how it stacks up in a direct contest. The best injection is the one a particular person will actually receive and tolerate.

Beyond the Needle: What Else Is Coming

Long-acting olanzapine is a better delivery of an old idea. But the field is also finally seeing some genuinely new ideas.

For most of the past seventy years, nearly every antipsychotic has worked, one way or another, by calming the brain’s dopamine signals. In September 2024, the FDA approved Cobenfy, a pill that works on a different system entirely, the brain’s muscarinic receptors. It was the first new type of schizophrenia medicine in decades. Early trials showed meaningful symptom relief without the usual weight gain or stiffness, though nausea, constipation, and dry mouth are common. It is not a perfect answer: a trial testing it as an add-on for people who were not fully helped by their current antipsychotic did not show a statistically significant benefit, and it still has to be taken twice daily, which brings back the very adherence problem LAIs try to solve. Researchers are also studying it for the hallucinations and agitation that can accompany Alzheimer’s disease.

Other hopefuls have stumbled. A closely watched drug called emraclidine failed to beat placebo in two mid-stage trials, a reminder of how hard it is to develop psychiatric medicines. Others, including newer agents aimed at the muscarinic system and drugs like brilaroxazine, are still working through trials.

And for the roughly one in three people whose symptoms do not respond to standard antipsychotics, clozapine remains the most effective option we have. It is underused partly because of the blood monitoring it requires, and no long-acting form exists.

The future likely looks like a menu rather than a single winner: new mechanisms for people who do not respond to the old ones, and better delivery systems, like Weltruza, for those who do respond but struggle to take daily medicine.

What Medicine Cannot Do Alone

I would like to end with something I wish more headlines said. A shot does not treat schizophrenia. It treats the part of schizophrenia that medication can reach.

Mr. M, the man from the emergency room, did eventually agree to a monthly injection. It was not a miracle. He still hears his name whispered occasionally, and he still struggles with sleep. But he has not been hospitalized since, and last month he told me he started volunteering at a community garden. It was not the injection that put the trowel in his hand. It was the housing coordinator, the peer-support group, the therapist who helped him make sense of his experiences, a brother who started calling every Sunday, and a long list of small, human things. The injection simply stopped the floor from giving way beneath all of it.

That, I think, is the real promise of long-acting medicines: not that they cure, but that they protect the quiet ordinary days on which a life gets rebuilt.

Article Author：Dr. Bob Lee, DO, MS, MBA
Chief Resident Physician, Department of Psychiatry & Behavioral Sciences
Child and Adolescent Psychiatry Fellow
Nassau University Medical Center